Clinical trial

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

NCT02407600

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2015-04-01

PhasePHASE2

Study timeline

Study start (unknown)2015-04-01Date precision: month

Registry last updated2015-04-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Vomitingunresolved

Nauseaunresolved

Emesisunresolved

Interventions

FOSAPREPITANT (Emend)DRUG

PlaceboDRUG

Sponsors & collaborators

Ajeet Gajralead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

SyracuseNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02407600 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.